Anti-extra domain B splice variant of fibronectin antibody drug conjugate eliminates tumors with enhanced efficacy when combined with checkpoint blockade

Overview of attention for article published in Molecular Cancer Therapeutics, July 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 1 news outlet

twitter: 7 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 19 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 12 X posts from 7 X users, with an upper bound of 3,081 followers.

@PropThinker $pyxs https://t.co/IZTH1CouAd

20 Apr 2023

Reply Repost Favourite

RT @MCT_AACR: Going to #AACR23 session on New Concepts in #DrugDiscovery and Engineering? Check out this article about an anti-extra domain…

19 Apr 2023

Reply Repost Favourite

Going to #AACR23 session on New Concepts in #DrugDiscovery and Engineering? Check out this article about an anti-extra domain B splice variant of fibronectin antibody drug conjugate by speaker Puja Sapra. https://t.co/4mxiTcL3Ur https://t.co/mhCZWTrMWO

19 Apr 2023

Reply Repost Favourite

#ICYMI: Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade. https://t.co/YbWnNEJABn https://t.co/i8otV0a7cs

30 Sep 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 8 additional X posts.